Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Keywords

MedicineLung cancerCancer researchImmune checkpointOncologyCancerImmune systemInternal medicineImmunotherapyImmunology

Affiliated Institutions

Related Publications

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis , Michael E. Goldberg , Danielle Greenawalt +66 more

Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups o...

2018 Cancer Discovery 1505 citations

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer

Chiara Lazzari , Alessandra Bulotta , Monika Ducceschi +5 more

Innovative therapeutic agents have significantly improved outcome with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, w...

2017 Frontiers in Medicine 36 citations

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Narjust Duma , Rafael Santana-Dávila , Julian R. Molina

Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer...

2019 Mayo Clinic Proceedings 2089 citations

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Valsamo Anagnostou , Kellie N. Smith , Patrick M. Forde +26 more

Abstract Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the ...

2016 Cancer Discovery 853 citations

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi , Matthew D. Hellmann , Alexandra Snyder +21 more

Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this...

2015 Science 7740 citations

Publication Info

Year: 2019
Type: article
Volume: 30
Issue: 8
Pages: 1321-1328
Citations: 1292
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1292

OpenAlex

Cite This

APA Style

                            
                                
                                    J. Mazieres, 
                                
                                    Alexander Drilon, 
                                
                                    Amélie Lusque
                                
                                et al.
                            
                            (2019). 
                            Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. 
                            Annals of Oncology
                            , 30
                            (8)
                            , 1321-1328.
                            https://doi.org/10.1093/annonc/mdz167
                        

Identifiers

DOI: 10.1093/annonc/mdz167